Vericel Management
Management Kriterienprüfungen 3/4
Vericel CEO ist Nick Colangelo , ernannt in Mar 2013, hat eine Amtszeit von 13.42 Jahren. Die jährliche Gesamtvergütung beträgt $11.16M , bestehend aus 7.7% Gehalt und 92.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.61% der Aktien des Unternehmens, im Wert von $13.63M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.9 Jahre bzw. 13.4 Jahre.
Wichtige Informationen
Nick Colangelo
Geschäftsführender
US$11.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 7.71% |
| Amtszeit als Geschäftsführer | 13.4yrs |
| Eigentum des Geschäftsführers | 0.6% |
| Durchschnittliche Amtszeit des Managements | 4.9yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 13.4yrs |
Jüngste Management Updates
Recent updates
Narrative-Update • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Narrative-Update • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Narrative-Update • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Analyseartikel • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Analyseartikel • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...Neues Narrative • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?Neues Narrative • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaAnalyseartikel • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Analyseartikel • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
Neues Narrative • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Analyseartikel • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Analyseartikel • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Analyseartikel • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Analyseartikel • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Analyseartikel • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$24m |
| Mar 31 2026 | n/a | n/a | US$21m |
| Dec 31 2025 | US$11m | US$860k | US$17m |
| Sep 30 2025 | n/a | n/a | US$13m |
| Jun 30 2025 | n/a | n/a | US$7m |
| Mar 31 2025 | n/a | n/a | US$3m |
| Dec 31 2024 | US$10m | US$830k | US$10m |
| Sep 30 2024 | n/a | n/a | US$4m |
| Jun 30 2024 | n/a | n/a | US$789k |
| Mar 31 2024 | n/a | n/a | US$451k |
| Dec 31 2023 | US$7m | US$790k | -US$3m |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$17m |
| Dec 31 2022 | US$9m | US$760k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$18m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$13m | US$730k | -US$7m |
| Sep 30 2021 | n/a | n/a | US$214k |
| Jun 30 2021 | n/a | n/a | US$9m |
| Mar 31 2021 | n/a | n/a | US$4m |
| Dec 31 2020 | US$4m | US$675k | US$3m |
| Sep 30 2020 | n/a | n/a | US$145k |
| Jun 30 2020 | n/a | n/a | -US$3k |
| Mar 31 2020 | n/a | n/a | -US$12m |
| Dec 31 2019 | US$5m | US$634k | -US$10m |
Vergütung im Vergleich zum Markt: NickDie Gesamtvergütung ($USD11.16M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.18M).
Entschädigung vs. Einkommen: NickDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Nick Colangelo (62 yo)
13.4yrs
Amtszeit
US$11,156,368
Vergütung
Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation since March 1, 2013 and served as its Treasurer since May 7, 2014. He has been...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.6m | |
| CFO & Treasurer | 5.6yrs | US$3.24m | 0.031% $ 697.4k | |
| Chief Operating Officer | 7.2yrs | US$3.62m | 0.032% $ 714.4k | |
| Chief Legal Officer | 6.8yrs | US$2.55m | 0.0032% $ 71.8k | |
| Chief Medical Officer | 8yrs | US$2.56m | 0.15% $ 3.3m | |
| Principal Accounting Officer | 4.5yrs | keine Daten | 0.0021% $ 47.1k | |
| Vice President of Finance & Investor Relations | no data | keine Daten | keine Daten | |
| Chief Marketing Officer | 1.6yrs | keine Daten | keine Daten | |
| Senior Vice President of Corporate Development & Strategy | 4.9yrs | keine Daten | keine Daten | |
| Senior Vice President of Sales | 2.6yrs | keine Daten | keine Daten | |
| Chief Human Resources Officer | 2.1yrs | US$3.21m | 0.0036% $ 80.8k | |
| Senior Vice President of Operations | 4.5yrs | keine Daten | keine Daten |
4.9yrs
Durchschnittliche Betriebszugehörigkeit
57.5yo
Durchschnittliches Alter
Erfahrenes Management: VCELDas Führungsteam des Unternehmens gilt als erfahren (4.9 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 13.4yrs | US$11.16m | 0.61% $ 13.6m | |
| Independent Director | 11.6yrs | US$357.80k | 0.036% $ 797.4k | |
| Independent Director | 11.6yrs | US$348.43k | 0.037% $ 819.2k | |
| Independent Chairman & Lead Director | 20.6yrs | US$395.30k | 0.064% $ 1.4m | |
| Independent Director | 20.9yrs | US$365.30k | 0.13% $ 2.8m | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 16.3yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 16.3yrs | keine Daten | keine Daten | |
| Independent Director | 13yrs | US$355.30k | 0.068% $ 1.5m | |
| Independent Director | 5.2yrs | US$342.80k | 0.031% $ 690.5k |
13.4yrs
Durchschnittliche Betriebszugehörigkeit
65.5yo
Durchschnittliches Alter
Erfahrener Vorstand: VCELDie Vorstandsmitglieder sind sehr erfahren ( 13.4 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 11:54 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Vericel Corporation wird von 20 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |